FANGZHOU JIANKE (06086) rose over 10% intraday, reaching a high of HK$1.03, a new high since June. As of press time, it was up 5.88% at HK$0.99.
Recently, the 10th Yuncan Tianyu Conference · Pharmaceutical Distribution Review and Certification Technology Meeting, themed "New Order · New Ecosystem, Coexistence of Regulation and Value," was held in Guangzhou. At the meeting, FANGZHOU JIANKE was successfully included in the compilation with its case "AI Algorithm-Based Pharmaceutical Procurement — Inventory Collaboration Digital Intelligence Platform Practice," further confirming the company's industry demonstration value in AI digital intelligence practices.
The company uses the Xingshi large model as its technical foundation to create a series of "AI + chronic disease services" digital intelligence solutions adapted to different service scenarios; at the same time, it accelerates the implementation of digital intelligence tools, relying on AI health managers and AI medication assistants to optimize user experience.
It is worth noting that in the first half of the year, FANGZHOU JIANKE achieved revenue of 1.8245 billion yuan, a year-on-year increase of 22.2%; adjusted net profit reached 18.708 million yuan, a year-on-year increase of 6.4%, maintaining a good momentum of sustained profitability. With its extensive and professional registered doctor resources, the company has built a medical service network covering multiple departments; its supply chain network covers more than 1,800 suppliers and more than 1,000 pharmaceutical companies, with economies of scale gradually emerging. In the first half of 2026, the repurchase rate of paying users of FANGZHOU JIANKE reached 89.2%.
Comments